Imclone’s board on Monday said Bristol-Myers Squibb’s $60-per-share takeover bid appeared too low but added that it would still hire advisers to study the unsolicited offer.
Carl Icahn, the billionaire investor and chairman of Imclone, said he opposed the bid because he believed that it “greatly undervalues” the company.
